Assessment of liver fibrosis with liver and spleen stiffness measured by sound touch elastography, serum fibrosis markers in patients with chronic hepatitis B

被引:10
|
作者
Dong, Bing Tian [1 ]
Huang, Shu [2 ]
Lyu, Guo Rong [1 ]
Qin, Ran [2 ]
Gu, Jiong Hui [3 ]
机构
[1] Fujian Med Univ, Dept Ultrasound, Affiliated Hosp 2, 34 North Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China
[2] Xiamen Univ, Dept Ultrasound, Chenggong Hosp, Xiamen, Fujian, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Ultrasound, Hangzhou, Zhejiang, Peoples R China
关键词
biomarkers; chronic hepatitis B; imaging technique; liver fibrosis; sound touch elastography; SHEAR-WAVE ELASTOGRAPHY; PORTAL-HYPERTENSION; ULTRASOUND ELASTOGRAPHY; TRANSIENT ELASTOGRAPHY; DIAGNOSTIC-ACCURACY; ESOPHAGEAL-VARICES; CLINICAL-USE; RECOMMENDATIONS; PERFORMANCE; PREDICTORS;
D O I
10.1111/1751-2980.12991
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives To evaluate the performance of liver stiffness (LS) and spleen stiffness (SS) by using the sound touch elastography (STE) technique and compare with those of the splenic index, aspartate transaminase-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) index, King's score and combined models for diagnosing and staging fibrosis in chronic hepatitis B (CHB). Methods One hundred patients with CHB underwent STE and serological tests. LS and SS values were measured with STE technique, and splenic index was calculated. Staging of fibrosis was determined with liver biopsy. Correlations between the individual parameters and the stage of fibrosis were evaluated with the Spearman correlation analysis. The area under the receiver operating characteristic curve (AUROC) was calculated to analyze the performance of all methods. Results Among all individual parameters, LS showed the highest AUROC for diagnosing fibrosis of >= S2, >= S3, and S4 stages (AUROC: 0.70, 0.86, and 0.96, respectively; all P < 0.05). The AUROC of combined model 1 (LS and SS) and 2 (LS, SS, APRI, FIB-4 index, King's score) for diagnosing >= S2, >= S3, and S4 fibrosis were 0.70, 0.86, 0.97, and 0.70, 0.86, 0.96, respectively, which were higher than those of APRI, FIB-4 index and the King's score (P < 0.05). No significant differences were found between two combined models and LS for staging fibrosis (P > 0.05). Conclusions LS measurement is reliable for diagnosing and staging fibrosis in CHB, with a better performance than SS, splenic index and serum biomarkers. It is also comparable with the performance of combined models.
引用
收藏
页码:342 / 350
页数:9
相关论文
共 50 条
  • [41] Noninvasive indirect serum markers of liver fibrosis in patients with chronic viral hepatitis
    Afyon, Murat
    Artuk, Cumhur
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2016, 27 (04): : 397 - 398
  • [42] Liver stiffness as measured by two-dimensional shear wave elastography overestimates the stage of fibrosis in patients with chronic hepatitis B and hepatic steatosis
    Xie, Xiaoyu
    Feng, Yuemin
    Lyu, Zhuozhen
    Wang, Le
    Yang, Yao
    Bai, Yuping
    Liu, Chenxi
    Wu, Hao
    Ren, Wanhua
    Zhu, Qiang
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (02)
  • [43] How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?
    Castera, Laurent
    Bedossa, Pierre
    [J]. LIVER INTERNATIONAL, 2011, 31 : 13 - 17
  • [44] DIAGNOSTIC VALUE OF POINT SHEAR WAVE ELASTOGRAPHY (pSWE) OF THE SPLEEN FOR ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS
    Doykova, Katia
    Doykov, Daniel
    Tsvetkova, Silvia
    Andonov, Vladimir
    [J]. COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES, 2024, 77 (06): : 892 - 898
  • [45] Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C
    Abdelsameea, Eman
    Alsebaey, Ayman
    Abdel-Razek, Wael
    Ehsan, Nermin
    Morad, Wesam
    Salama, Mohsen
    Waked, Imam
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (12) : 1553 - 1558
  • [46] Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool?
    Stasi, C.
    Arena, U.
    Vizzutti, F.
    Zignego, A. L.
    Monti, M.
    Laffi, G.
    Corti, G.
    Pinzani, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2009, 41 (12) : 863 - 866
  • [47] INDEPENDENT INFLUENCERS OF TRANSIENT ELASTOGRAPHY ASSESSMENT OF LIVER FIBROSIS IN HEPATITIS B AND HEPATITIS C PATIENTS
    Fraquelli, M.
    Rigamonti, C.
    Casazza, G.
    Donato, M. F.
    Conte, D.
    Ronchi, G.
    Massironi, S.
    Rumi, M.
    Lampertico, P.
    Colombo, M.
    [J]. JOURNAL OF HEPATOLOGY, 2009, 50 : S78 - S78
  • [48] Diagnosis of Liver Fibrosis in Patients with Chronic Hepatitis and Nonalcoholic Steatohepatitis Using Serum Enhanced Liver Fibrosis (ELF) score and Ultrasound Elastography
    Takashima, Tomoyuki
    Iijima, Hiroko
    Aizawa, Nobuhiro
    Ishii, Akio
    Sakai, Yoshiyuki
    Iwata, Kazunari
    Ikeda, Naoto
    Tanaka, Hironori
    Iwata, Yoshinori
    Enomoto, Hirayuki
    Saito, Masaki
    Imanishi, Hiroyasu
    Nakashima, Osamu
    Yano, Hirohisa
    Nishiguchi, Shuhei
    [J]. HEPATOLOGY, 2012, 56 : 812A - 813A
  • [49] Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
    Tsuji, Yuki
    Namisaki, Tadashi
    Kaji, Kosuke
    Takaya, Hiroaki
    Nakanishi, Keisuke
    Sato, Shinya
    Saikawa, Soichiro
    Sawada, Yasuhiko
    Kitagawa, Kou
    Shimozato, Naotaka
    Kawaratani, Hideto
    Moriya, Kei
    Noguchi, Ryuichi
    Akahane, Takemi
    Mitoro, Akira
    Yoshiji, Hitoshi
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (02) : 985 - 995
  • [50] On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients
    Wong, Grace Lai-Hung
    Wong, Vincent Wai-Sun
    Choi, Paul Cheung-Lung
    Chan, Anthony Wing-Hung
    Chim, Angel Mei-Ling
    Yiu, Karen Ka-Lam
    Chu, Shirley Hoi-Ting
    Chan, Francis Ka-Leung
    Sung, Joseph Jao-Yao
    Chan, Henry Lik-Yuen
    [J]. ANTIVIRAL THERAPY, 2011, 16 (02) : 165 - 172